Business Description
VISEN Pharmaceuticals
ISIN : KYG93Y5D1039
Total Employee Number:
82Compare
Compare
Traded in other countries / regions
02561.Hong KongT06.Germany IPO Date
2025-03-21Description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.86 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.78 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 7.5 | |||||
3-Year EPS without NRI Growth Rate | 7.5 | |||||
3-Year FCF Growth Rate | -17.4 | |||||
3-Year Book Growth Rate | 3.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.85 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1493.61 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.02 | |||||
9-Day RSI | 52.95 | |||||
14-Day RSI | 50.12 | |||||
3-1 Month Momentum % | -10.79 | |||||
6-1 Month Momentum % | -38.99 | |||||
12-1 Month Momentum % | -55.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4 | |||||
Quick Ratio | 3.74 | |||||
Cash Ratio | 2.38 | |||||
Days Inventory | 635.8 | |||||
Days Sales Outstanding | 184.39 | |||||
Days Payable | 94.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -8.55 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.51 | |||||
Operating Margin % | -623.74 | |||||
Net Margin % | -672.7 | |||||
EBITDA Margin % | -653.79 | |||||
FCF Margin % | -1277.91 | |||||
OCF Margin % | -1276.3 | |||||
ROE % | -31.72 | |||||
ROA % | -26.28 | |||||
ROIC % | -89.01 | |||||
3-Year ROIIC % | 47.14 | |||||
ROC (Joel Greenblatt) % | -115.03 | |||||
ROCE % | -31.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 54.29 | |||||
PB Ratio | 2.93 | |||||
Price-to-Tangible-Book | 2.93 | |||||
EV-to-EBIT | -7.09 | |||||
EV-to-EBITDA | -7.2 | |||||
EV-to-Revenue | 47.07 | |||||
EV-to-FCF | -3.68 | |||||
| Price-to-Net-Current-Asset-Value | 3.1 | |||||
| Price-to-Net-Cash | 6.77 | |||||
Earnings Yield (Greenblatt) % | -14.1 | |||||
FCF Yield % | -22.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VISEN Pharmaceuticals Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 40.137 | ||
| EPS (TTM) (HK$) | -2.491 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 31 | ||
| 14-Day RSI | 50.12 | ||
| 14-Day ATR (HK$) | 0.419068 | ||
| 20-Day SMA (HK$) | 19.923 | ||
| 12-1 Month Momentum % | -55.67 | ||
| 52-Week Range (HK$) | 18.5 - 47.1 | ||
| Shares Outstanding (Mil) | 113.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VISEN Pharmaceuticals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VISEN Pharmaceuticals Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
VISEN Pharmaceuticals Frequently Asked Questions
What is VISEN Pharmaceuticals(HKSE:02561)'s stock price today?
The current price of HKSE:02561 is HK$19.98. The 52 week high of HKSE:02561 is HK$47.10 and 52 week low is HK$18.50.
When is next earnings date of VISEN Pharmaceuticals(HKSE:02561)?
The next earnings date of VISEN Pharmaceuticals(HKSE:02561) is .
Does VISEN Pharmaceuticals(HKSE:02561) pay dividends? If so, how much?
VISEN Pharmaceuticals(HKSE:02561) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on VISEN Pharmaceuticals
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers